BioPharma Blue Cross settles class action suit naming ‘pharma bro’ Martin Shkreli for $28M By Michael Schroeder
Legal, BioPharma, Payers Insurers sue ‘pharma bro’ Martin Shkreli, company for alleged price gouging By Anuja Vaidya
BioPharma, Legal Martin Shkreli, his former company thwarted generic competition against toxoplasmosis drug, FTC says By Alaric DeArment
Kaiser, Pharma Martin Shkreli’s in prison but Daraprim prices are still high By Shefali Luthra, Kaiser Health News
Pharma Former attorney to pharma bro Martin Shkreli found guilty in fraud scheme By Kathryn Rubino, Above The Law
Top Story Shkreli the gateway musical: 5 more health and life science dramas that should get a shot on Broadway By Stephanie Baum and Neil Versel
Top Story Morning Read: Childhood pals accused of insider trading on Pfizer acquisitions, Shkreli hit with conspiracy charge By Neil Versel
